<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">205</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>HEPATOCELLULAR CARCINOMA TREATMENT; NONSURGICAL APPROACHES&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alnaggar</surname><given-names>Mohammed</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>22</day><month>08</month><year>2016</year></pub-date><volume>)</volume><issue/><fpage>1</fpage><lpage>4</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Primary liver cancer (PLC) is one of the common cancers with high incidence and poor prognosis. PLC has become one of the major diseases that causes serious harm to human health and life. In recent years, domestic and foreign researchers have studied and summarized the current status of primary liver cancer treatment, and have made great progress as well. Significant progress in terms of early diagnosis, surgical treatment, and comprehensive treatment of liver cancer results in improvement in patient__ampersandsignrsquo;s quality of life. So far, there are many available methods that can be used to improve the quality of life in these patients, but still there are many issues that need to be addressed intensively. The progress in the study of liver cancer may bring about a new hope for the treatment of liver cancer.&#13;
Non-surgical treatment plays an important role in the treatment of primary liver cancer, which includes transcatheter arterial chemoembolization, percutaneous ablation therapy, radiation therapy, chemotherapy, etc&#13;
</p></abstract><kwd-group><kwd>Primary liver cancer; Non-surgical treatments progress</kwd><kwd> Quality of life</kwd></kwd-group></article-meta></front></article>
